Dongwha Pharm

DONGWHA is the company that "serves customers by making good medicines and is managed with the rewards generated by benefits of good medicines." Under its corporate philosophy that places the foremost priority on health and safety of its customers, it continues to work toward happiness of customers.

Based on respect for the shared value that "we work diligently in our youth and live fruitful lives in old age." it serves every customer faithfully by fostering ownership and faith among its members.

Donghwa Pharmaceutical Research Institute has established a development strategy to actively cope with rapidly changing domestic and overseas pharmaceutical markets. That is, the institute plans to appropriately allocate the research proportion of the development of new drugs and products to achieve stable growth in the near and short-term future, and to gradually expand the development of new formulations and drugs for competitiveness in the long term. Based on the experience and technology accumulated so far, the institute has been focusing on areas that can maximize its core competencies, and has been maximizing its research productivity through joint industry-academia research and outsourcing in areas where it is weak.

The representative cases include the successful development of a new drug, Milican Injection, which is the world's first radiopharmaceutical for the treatment of liver cancer, the technological transfer of a candidate for osteoporosis treatment (DW1350), and the acquisition of the NET certificate for Zabolante (Zabofloxacin), a quinolone antibacterial agent by the Ministry of Health and Welfare. Following the success, the company was recognized for the following : 'World-Class Korean Product', 'Top 10 Technologies in Korea', 'Dasan Technology Award', 'Korea New Drug Award', 'Industry-Academia Cooperation Award', 'Dongam Pharmaceutical Award' and 'Bronze Tower, Order of Industrial Service Merit', and made a significant contribution toward the development of new drugs in the domestic pharmaceutical industry.